Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Immune Network
;
: 8-2020.
Artículo
en Inglés
| WPRIM
| ID: wpr-811174
ABSTRACT
Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Biopsia
/
Biomarcadores
/
Resultado Fatal
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
/
Antígeno B7-H1
/
Receptor de Muerte Celular Programada 1
/
Aceleración
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Immune Network
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS